Outcome of DOTS: effectiveness assessment of treatment among tuberculosis patients in Guinea

AJBM crossMark

Bernt F. Lindtjørn¹, Wonder G. Phiri², Gillian D. Mann³*


TB contributes in Guinea (PNG), significantly to the burden of disease. In 2014, the WHO estimate of incidence was 417 cases per 100,000 people. The aim of the study was to assess trends in the expansion of DOTS and treatment outcomes for tuberculosis in Guinea. Retrospective study was conducted during the 2015 and 2016, the collected data were analyzed for treatment and outcomes, and success rates. 162 TB cases were enrolled in this study. The data showed that more cases registered in the young age groups (20.4%), with 1.7:1 male to female ratio. Sputum-smear positive for AFB was 34.6%. Furthermore, cured, completed treatment, defaulter, treatment failure, died) of 56 patients are (69.6%, 9%, 16%, 3.6%, 0.0%) respectively. Our results concluded that further studies are recommended to see the impact of the DOTS programme on the prevalence and incidence of tuberculosis.

Keywords: Sputum-smear positive; DOTS; Retrospective study; Guinea

Copyright © 2017 by The American Society for BioMedicine and BM-Publisher, Inc.

Article citationReferencesFull-Text/PDFFeedback
The citation data is computed by the following citation measuring services:

Cited by (CrossRef)
Google Scholar

  1. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516–28. doi: 10.1183/09031936.00073611 [PubMed]
  2. Guidelines for treatment of tuberculosis. 4th ed. (WHO/HTM/TB/2009.420). Geneva, World Health Organization. 2009. Available: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf.
  3. Gilpin CM, Simpson G, Vincent S, et al. Evidence of primary transmission of multidrug-resistant TB in the Western Province of Papua New GuineaMed. J 2008;188:148–152. [PubMed]
  4. Dutta NK, Alsultan A, Peloquin CA, Karakousis PC. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother 2013;57:1535–1537. doi:10.1128/AAC.01933-12. [PMC free article] [PubMed] [Cross Ref]
  5. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 2011;6:e17556. doi:10.1371/journal.pone.0017556. [PMC free article] [PubMed] [Cross Ref]
    22. Aly S, Wagner K, Keller C, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 2006;210:298–305. doi:10.1002/path.2055. [PubMed] [Cross Ref]
    23. Stinson K, Kurepina N, Venter A, et al. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 2016;60:3316–3322. doi:10.1128/AAC.03014-15. [PMC free article] [PubMed] [Cross Ref]
  6. Boon C, Li R, Qi R, Dick T. Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol 2001;183:2672–2676. doi:10.1128/JB.183.8.2672-2676. [PMC free article][PubMed] [Cross Ref]
  7. Boon C, Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 2002;184:6760–6767. doi:10.1128/JB.184.24.6760-6767. [PMC free article] [PubMed][Cross Ref]
  8. Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later. Future Microbiol 2012;7:513–518. doi:10.2217/fmb.12.14. [PubMed] [Cross Ref]
  9. Rosenkrands I, Slayden RA, Crawford J, et al. Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol 2002;184:3485–3491. doi:10.1128/JB.184.13.3485-3491.2002. [PMC free article] [PubMed] [Cross Ref]
  10. Park H-D, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003;48:833–843. doi:10.1046/j.1365-2958.2003.03474.x. [PMC free article] [PubMed][Cross Ref]
  11. Lim A, Eleuterio M, Hutter B, Murugasu-Oei B, Dick T. Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J Bacteriol 199;181:2252–2256. [PMC free article] [PubMed]
  12. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054–2058. doi:10.1128/AAC.38.9.2054. [PMC free article] [PubMed] [Cross Ref]
  13. Ahmad Z, Klinkenberg LG, Pinn ML, et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009;200:1136–1143. doi:10.1086/605605.[PubMed] [Cross Ref]
  14. Ahmad Z, Nuermberger EL, Tasneen R, et al. Comparison of the “Denver regimen” against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 2010;65:729–734. doi:10.1093/jac/dkq007. [PMC free article] [PubMed] [Cross Ref]
  15. Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461–499. doi:10.1086/431984.[PubMed] [Cross Ref]
  16. Peloquin CA, Hadad DJ, Molino LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:852–857. doi:10.1128/AAC.01036-07. [PMC free article] [PubMed][Cross Ref]
  17. Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2008;82:91–96. doi:10.1054/tube.2002.0330. [PubMed] [Cross Ref]
    38. Dutta NK, Pinn ML, Zhao M, Rudek MA, Karakousis PC. 2013. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosisJ Antimicrob Chemother 68:1327–1330. doi:10.1093/jac/dkt037. [PMC free article] [PubMed] [Cross Ref]
  18. Simpson G, Coulter C, Weston J, et al. Resistance patterns of multidrug-resistant TB in Western Province, Papua New Guinea. Int. J. Tuberc. Lung Dis 2011; 15:551–552. doi: 10.5588/ijtld.10.0347[PubMed]
  19. Ballif M, Harino P, Ley S, et al. Insight into the genetic diversity of Mycobacterium TB in Madang, Papua New Guinea. Submitted for publication. [PubMed]
  20. Cross GB, Coles K, Nikpour M, et al. TB incidence and characteristics in the remote gulf province of Papua New Guinea: a prospective study. BMC Infect Dis 2014;14:93 doi: 10.1186/1471-2334-14-93 [PMC free article] [PubMed]
  21. Ley S, Harino P, Vanuga K, et al. Diversity of Mycobacterium tuberculosis and drug resistance in different provinces of Papua New Guinea. BMC microbiology 2014;14(1):307. [PMC free article] [PubMed]
  22. WHO. Guidelines for surveillance of drug resistance in tuberculosis. 5th edn. (2015)., Geneva, World Health Organization. (WHO/HTM/TB.13.2015). 2015.
  23. Young F, Critchley JA, Johnstone LK, Unwin NC. A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalization. Glob Health 2009;5:9 doi: 10.1186/1744-8603-5-9 [PMC free article] [PubMed]
  24. WHO. Global Health Observatory WHO (WHO). Equatorial Guinea: WHO statistical profile. [Internet]. 2015. Available: http://www.who.int/gho/countries/gnq/country_profiles/en/
  25. Palaci M, Dietze R, Hadad DJ, et al. Cavitary Disease and Quantitative Sputum Bacillary Load in Cases of Pulmonary Tuberculosis. J Clin Microbiol 2007;45:4064–4066. doi: 10.1128/JCM.01780-07 [PMC free article] [PubMed]
  26. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007;4:e238 doi: 10.1371/journal.pmed.0040238 [PMC free article] [PubMed]
  27. Barnestein-Fonseca P, Leiva-Fernández J, Vidal-España F, et al. Is it possible to diagnose the therapeutic adherence of patients with COPD in clinical practice? A cohort study. BMC Pulm Med 2011;11:6 doi: 10.1186/1471-2466-11-6 [PMC free article][PubMed]
  28. Islam T, Hiatt T, Hennig C, Nishikiori N. Drug-resistant tuberculosis in the WHO Western Pacific Region. Western Pac Surveill Response J 2014;5 http://dx.doi.org/10.5365/wpsar.2014.5.4.007[PMC free article] [PubMed]
  29. Tuberculosis Control Program, Monitoring and Evaluation, Annual Report 2013, Government of Papua; New Guinea, August 2014.
  30. Papua New Guinea country guidelines for the programatic management of drug resistant tuberculosis, National TB programme unit, Disease control branch, National Department of Health, 2011.


1. Access this article through OpenAthens

2. Access this article through your login credentials/Subscription

" target="blank" background="#dde9f7" color="#171a1b" size="4"]Get Access

3. Purchase this article at rate $55.00 and received Full-Text/PDF
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, will be asked to supply your billing card information. Before continue with your purchase please read carefully the BM-Publisher terms and conditions of purchase.

Purchase Article

For any technique error please contact us and will be response to sending purchase article by email.

Who Can Become a Reviewer?
Any expert in the article's research field can become a reviewer with American Journal of Biomedicine. Editors might ask you to look at a specific aspect of an article,...

Find out more

Thank you for visiting American Journal of BioMedicine. * = Required fields

Error: Contact form not found.

Research Article
DOI: http://dx.doi.org/10.18081/2333-5106/017-5/231-242
American Journal of BioMedicine Volume 5, Issue 5, pages 231-242
Received January 11, 2017; accepted April 02, 2017; published May 11, 2017

How to cite this article
Lindtjørn BF, Phiri WG, GMann GD. Outcome of DOTS: effectiveness assessment of treatment among tuberculosis patients in Guinea. American Journal of BioMedicine 2017;5(5):231-242.

Case report outline
1. Abstract
2. Keywords
3. Introduction
4. Methods
5. Results
6. Discussion
7. References